The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antihormonal Cancer Therapies Market Research Report 2025
Synopsis
Antihormonal Cancer Therapy is a treatment with drugs, surgery, or radiation in order to block the production or action of a hormone. Antihormone therapy may be used in cancer treatment because certain hormones are able to stimulate the growth of some types of tumors.
The global Antihormonal Cancer Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antihormonal Cancer Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihormonal Cancer Therapies.
Report Scope
The Antihormonal Cancer Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihormonal Cancer Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihormonal Cancer Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
Samyang Biopharmaceuticals
Tolmar
Bluebird Bio
Bristol-Myers Squibb
Exelixis
Guardant Health
Illumina
Novartis
Merck KGaA
AbbVie
Gilead Sciences
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co.
Sanofi
Bayer
Segment by Type
Radiations
Drugs
Surgeries
Others
Segment by Application
Breast Cancer
Prostate Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihormonal Cancer Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antihormonal Cancer Therapy is a treatment with drugs, surgery, or radiation in order to block the production or action of a hormone. Antihormone therapy may be used in cancer treatment because certain hormones are able to stimulate the growth of some types of tumors.
The global Antihormonal Cancer Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antihormonal Cancer Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihormonal Cancer Therapies.
Report Scope
The Antihormonal Cancer Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihormonal Cancer Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihormonal Cancer Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
Samyang Biopharmaceuticals
Tolmar
Bluebird Bio
Bristol-Myers Squibb
Exelixis
Guardant Health
Illumina
Novartis
Merck KGaA
AbbVie
Gilead Sciences
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co.
Sanofi
Bayer
Segment by Type
Radiations
Drugs
Surgeries
Others
Segment by Application
Breast Cancer
Prostate Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihormonal Cancer Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihormonal Cancer Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Radiations
1.2.3 Drugs
1.2.4 Surgeries
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antihormonal Cancer Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antihormonal Cancer Therapies Market Perspective (2019-2030)
2.2 Antihormonal Cancer Therapies Growth Trends by Region
2.2.1 Global Antihormonal Cancer Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antihormonal Cancer Therapies Historic Market Size by Region (2019-2024)
2.2.3 Antihormonal Cancer Therapies Forecasted Market Size by Region (2025-2030)
2.3 Antihormonal Cancer Therapies Market Dynamics
2.3.1 Antihormonal Cancer Therapies Industry Trends
2.3.2 Antihormonal Cancer Therapies Market Drivers
2.3.3 Antihormonal Cancer Therapies Market Challenges
2.3.4 Antihormonal Cancer Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antihormonal Cancer Therapies Players by Revenue
3.1.1 Global Top Antihormonal Cancer Therapies Players by Revenue (2019-2024)
3.1.2 Global Antihormonal Cancer Therapies Revenue Market Share by Players (2019-2024)
3.2 Global Antihormonal Cancer Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antihormonal Cancer Therapies Revenue
3.4 Global Antihormonal Cancer Therapies Market Concentration Ratio
3.4.1 Global Antihormonal Cancer Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihormonal Cancer Therapies Revenue in 2023
3.5 Antihormonal Cancer Therapies Key Players Head office and Area Served
3.6 Key Players Antihormonal Cancer Therapies Product Solution and Service
3.7 Date of Enter into Antihormonal Cancer Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antihormonal Cancer Therapies Breakdown Data by Type
4.1 Global Antihormonal Cancer Therapies Historic Market Size by Type (2019-2024)
4.2 Global Antihormonal Cancer Therapies Forecasted Market Size by Type (2025-2030)
5 Antihormonal Cancer Therapies Breakdown Data by Application
5.1 Global Antihormonal Cancer Therapies Historic Market Size by Application (2019-2024)
5.2 Global Antihormonal Cancer Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antihormonal Cancer Therapies Market Size (2019-2030)
6.2 North America Antihormonal Cancer Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antihormonal Cancer Therapies Market Size by Country (2019-2024)
6.4 North America Antihormonal Cancer Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antihormonal Cancer Therapies Market Size (2019-2030)
7.2 Europe Antihormonal Cancer Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antihormonal Cancer Therapies Market Size by Country (2019-2024)
7.4 Europe Antihormonal Cancer Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antihormonal Cancer Therapies Market Size (2019-2030)
8.2 Asia-Pacific Antihormonal Cancer Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antihormonal Cancer Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific Antihormonal Cancer Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antihormonal Cancer Therapies Market Size (2019-2030)
9.2 Latin America Antihormonal Cancer Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antihormonal Cancer Therapies Market Size by Country (2019-2024)
9.4 Latin America Antihormonal Cancer Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antihormonal Cancer Therapies Market Size (2019-2030)
10.2 Middle East & Africa Antihormonal Cancer Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antihormonal Cancer Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa Antihormonal Cancer Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Antihormonal Cancer Therapies Introduction
11.1.4 Roche Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Antihormonal Cancer Therapies Introduction
11.2.4 Amgen Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Samyang Biopharmaceuticals
11.3.1 Samyang Biopharmaceuticals Company Detail
11.3.2 Samyang Biopharmaceuticals Business Overview
11.3.3 Samyang Biopharmaceuticals Antihormonal Cancer Therapies Introduction
11.3.4 Samyang Biopharmaceuticals Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.3.5 Samyang Biopharmaceuticals Recent Development
11.4 Tolmar
11.4.1 Tolmar Company Detail
11.4.2 Tolmar Business Overview
11.4.3 Tolmar Antihormonal Cancer Therapies Introduction
11.4.4 Tolmar Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.4.5 Tolmar Recent Development
11.5 Bluebird Bio
11.5.1 Bluebird Bio Company Detail
11.5.2 Bluebird Bio Business Overview
11.5.3 Bluebird Bio Antihormonal Cancer Therapies Introduction
11.5.4 Bluebird Bio Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.5.5 Bluebird Bio Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Antihormonal Cancer Therapies Introduction
11.6.4 Bristol-Myers Squibb Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Exelixis
11.7.1 Exelixis Company Detail
11.7.2 Exelixis Business Overview
11.7.3 Exelixis Antihormonal Cancer Therapies Introduction
11.7.4 Exelixis Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.7.5 Exelixis Recent Development
11.8 Guardant Health
11.8.1 Guardant Health Company Detail
11.8.2 Guardant Health Business Overview
11.8.3 Guardant Health Antihormonal Cancer Therapies Introduction
11.8.4 Guardant Health Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.8.5 Guardant Health Recent Development
11.9 Illumina
11.9.1 Illumina Company Detail
11.9.2 Illumina Business Overview
11.9.3 Illumina Antihormonal Cancer Therapies Introduction
11.9.4 Illumina Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.9.5 Illumina Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Antihormonal Cancer Therapies Introduction
11.10.4 Novartis Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.10.5 Novartis Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Detail
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Antihormonal Cancer Therapies Introduction
11.11.4 Merck KGaA Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.11.5 Merck KGaA Recent Development
11.12 AbbVie
11.12.1 AbbVie Company Detail
11.12.2 AbbVie Business Overview
11.12.3 AbbVie Antihormonal Cancer Therapies Introduction
11.12.4 AbbVie Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.12.5 AbbVie Recent Development
11.13 Gilead Sciences
11.13.1 Gilead Sciences Company Detail
11.13.2 Gilead Sciences Business Overview
11.13.3 Gilead Sciences Antihormonal Cancer Therapies Introduction
11.13.4 Gilead Sciences Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.13.5 Gilead Sciences Recent Development
11.14 Johnson & Johnson
11.14.1 Johnson & Johnson Company Detail
11.14.2 Johnson & Johnson Business Overview
11.14.3 Johnson & Johnson Antihormonal Cancer Therapies Introduction
11.14.4 Johnson & Johnson Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.14.5 Johnson & Johnson Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Antihormonal Cancer Therapies Introduction
11.15.4 Pfizer Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 Takeda
11.16.1 Takeda Company Detail
11.16.2 Takeda Business Overview
11.16.3 Takeda Antihormonal Cancer Therapies Introduction
11.16.4 Takeda Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.16.5 Takeda Recent Development
11.17 Eli Lilly
11.17.1 Eli Lilly Company Detail
11.17.2 Eli Lilly Business Overview
11.17.3 Eli Lilly Antihormonal Cancer Therapies Introduction
11.17.4 Eli Lilly Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.17.5 Eli Lilly Recent Development
11.18 AstraZeneca
11.18.1 AstraZeneca Company Detail
11.18.2 AstraZeneca Business Overview
11.18.3 AstraZeneca Antihormonal Cancer Therapies Introduction
11.18.4 AstraZeneca Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.18.5 AstraZeneca Recent Development
11.19 Astellas
11.19.1 Astellas Company Detail
11.19.2 Astellas Business Overview
11.19.3 Astellas Antihormonal Cancer Therapies Introduction
11.19.4 Astellas Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.19.5 Astellas Recent Development
11.20 Merck & Co.
11.20.1 Merck & Co. Company Detail
11.20.2 Merck & Co. Business Overview
11.20.3 Merck & Co. Antihormonal Cancer Therapies Introduction
11.20.4 Merck & Co. Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.20.5 Merck & Co. Recent Development
11.21 Sanofi
11.21.1 Sanofi Company Detail
11.21.2 Sanofi Business Overview
11.21.3 Sanofi Antihormonal Cancer Therapies Introduction
11.21.4 Sanofi Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.21.5 Sanofi Recent Development
11.22 Bayer
11.22.1 Bayer Company Detail
11.22.2 Bayer Business Overview
11.22.3 Bayer Antihormonal Cancer Therapies Introduction
11.22.4 Bayer Revenue in Antihormonal Cancer Therapies Business (2019-2024)
11.22.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antihormonal Cancer Therapies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Radiations
Table 3. Key Players of Drugs
Table 4. Key Players of Surgeries
Table 5. Key Players of Others
Table 6. Global Antihormonal Cancer Therapies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Antihormonal Cancer Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Antihormonal Cancer Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Antihormonal Cancer Therapies Market Share by Region (2019-2024)
Table 10. Global Antihormonal Cancer Therapies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Antihormonal Cancer Therapies Market Share by Region (2025-2030)
Table 12. Antihormonal Cancer Therapies Market Trends
Table 13. Antihormonal Cancer Therapies Market Drivers
Table 14. Antihormonal Cancer Therapies Market Challenges
Table 15. Antihormonal Cancer Therapies Market Restraints
Table 16. Global Antihormonal Cancer Therapies Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Antihormonal Cancer Therapies Market Share by Players (2019-2024)
Table 18. Global Top Antihormonal Cancer Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihormonal Cancer Therapies as of 2023)
Table 19. Ranking of Global Top Antihormonal Cancer Therapies Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Antihormonal Cancer Therapies Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antihormonal Cancer Therapies Product Solution and Service
Table 23. Date of Enter into Antihormonal Cancer Therapies Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antihormonal Cancer Therapies Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Antihormonal Cancer Therapies Revenue Market Share by Type (2019-2024)
Table 27. Global Antihormonal Cancer Therapies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Antihormonal Cancer Therapies Revenue Market Share by Type (2025-2030)
Table 29. Global Antihormonal Cancer Therapies Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Antihormonal Cancer Therapies Revenue Market Share by Application (2019-2024)
Table 31. Global Antihormonal Cancer Therapies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Antihormonal Cancer Therapies Revenue Market Share by Application (2025-2030)
Table 33. North America Antihormonal Cancer Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Antihormonal Cancer Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Antihormonal Cancer Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Antihormonal Cancer Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Antihormonal Cancer Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Antihormonal Cancer Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Antihormonal Cancer Therapies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Antihormonal Cancer Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Antihormonal Cancer Therapies Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Antihormonal Cancer Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Antihormonal Cancer Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Antihormonal Cancer Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Antihormonal Cancer Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Antihormonal Cancer Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Antihormonal Cancer Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 48. Roche Company Detail
Table 49. Roche Business Overview
Table 50. Roche Antihormonal Cancer Therapies Product
Table 51. Roche Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 52. Roche Recent Development
Table 53. Amgen Company Detail
Table 54. Amgen Business Overview
Table 55. Amgen Antihormonal Cancer Therapies Product
Table 56. Amgen Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 57. Amgen Recent Development
Table 58. Samyang Biopharmaceuticals Company Detail
Table 59. Samyang Biopharmaceuticals Business Overview
Table 60. Samyang Biopharmaceuticals Antihormonal Cancer Therapies Product
Table 61. Samyang Biopharmaceuticals Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 62. Samyang Biopharmaceuticals Recent Development
Table 63. Tolmar Company Detail
Table 64. Tolmar Business Overview
Table 65. Tolmar Antihormonal Cancer Therapies Product
Table 66. Tolmar Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 67. Tolmar Recent Development
Table 68. Bluebird Bio Company Detail
Table 69. Bluebird Bio Business Overview
Table 70. Bluebird Bio Antihormonal Cancer Therapies Product
Table 71. Bluebird Bio Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 72. Bluebird Bio Recent Development
Table 73. Bristol-Myers Squibb Company Detail
Table 74. Bristol-Myers Squibb Business Overview
Table 75. Bristol-Myers Squibb Antihormonal Cancer Therapies Product
Table 76. Bristol-Myers Squibb Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 77. Bristol-Myers Squibb Recent Development
Table 78. Exelixis Company Detail
Table 79. Exelixis Business Overview
Table 80. Exelixis Antihormonal Cancer Therapies Product
Table 81. Exelixis Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 82. Exelixis Recent Development
Table 83. Guardant Health Company Detail
Table 84. Guardant Health Business Overview
Table 85. Guardant Health Antihormonal Cancer Therapies Product
Table 86. Guardant Health Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 87. Guardant Health Recent Development
Table 88. Illumina Company Detail
Table 89. Illumina Business Overview
Table 90. Illumina Antihormonal Cancer Therapies Product
Table 91. Illumina Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 92. Illumina Recent Development
Table 93. Novartis Company Detail
Table 94. Novartis Business Overview
Table 95. Novartis Antihormonal Cancer Therapies Product
Table 96. Novartis Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Merck KGaA Company Detail
Table 99. Merck KGaA Business Overview
Table 100. Merck KGaA Antihormonal Cancer Therapies Product
Table 101. Merck KGaA Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 102. Merck KGaA Recent Development
Table 103. AbbVie Company Detail
Table 104. AbbVie Business Overview
Table 105. AbbVie Antihormonal Cancer Therapies Product
Table 106. AbbVie Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 107. AbbVie Recent Development
Table 108. Gilead Sciences Company Detail
Table 109. Gilead Sciences Business Overview
Table 110. Gilead Sciences Antihormonal Cancer Therapies Product
Table 111. Gilead Sciences Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 112. Gilead Sciences Recent Development
Table 113. Johnson & Johnson Company Detail
Table 114. Johnson & Johnson Business Overview
Table 115. Johnson & Johnson Antihormonal Cancer Therapies Product
Table 116. Johnson & Johnson Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 117. Johnson & Johnson Recent Development
Table 118. Pfizer Company Detail
Table 119. Pfizer Business Overview
Table 120. Pfizer Antihormonal Cancer Therapies Product
Table 121. Pfizer Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 122. Pfizer Recent Development
Table 123. Takeda Company Detail
Table 124. Takeda Business Overview
Table 125. Takeda Antihormonal Cancer Therapies Product
Table 126. Takeda Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 127. Takeda Recent Development
Table 128. Eli Lilly Company Detail
Table 129. Eli Lilly Business Overview
Table 130. Eli Lilly Antihormonal Cancer Therapies Product
Table 131. Eli Lilly Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 132. Eli Lilly Recent Development
Table 133. AstraZeneca Company Detail
Table 134. AstraZeneca Business Overview
Table 135. AstraZeneca Antihormonal Cancer Therapies Product
Table 136. AstraZeneca Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 137. AstraZeneca Recent Development
Table 138. Astellas Company Detail
Table 139. Astellas Business Overview
Table 140. Astellas Antihormonal Cancer Therapies Product
Table 141. Astellas Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 142. Astellas Recent Development
Table 143. Merck & Co. Company Detail
Table 144. Merck & Co. Business Overview
Table 145. Merck & Co. Antihormonal Cancer Therapies Product
Table 146. Merck & Co. Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 147. Merck & Co. Recent Development
Table 148. Sanofi Company Detail
Table 149. Sanofi Business Overview
Table 150. Sanofi Antihormonal Cancer Therapies Product
Table 151. Sanofi Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 152. Sanofi Recent Development
Table 153. Bayer Company Detail
Table 154. Bayer Business Overview
Table 155. Bayer Antihormonal Cancer Therapies Product
Table 156. Bayer Revenue in Antihormonal Cancer Therapies Business (2019-2024) & (US$ Million)
Table 157. Bayer Recent Development
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antihormonal Cancer Therapies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Antihormonal Cancer Therapies Market Share by Type: 2023 VS 2030
Figure 3. Radiations Features
Figure 4. Drugs Features
Figure 5. Surgeries Features
Figure 6. Others Features
Figure 7. Global Antihormonal Cancer Therapies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Antihormonal Cancer Therapies Market Share by Application: 2023 VS 2030
Figure 9. Breast Cancer Case Studies
Figure 10. Prostate Cancer Case Studies
Figure 11. Other Case Studies
Figure 12. Antihormonal Cancer Therapies Report Years Considered
Figure 13. Global Antihormonal Cancer Therapies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Antihormonal Cancer Therapies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Antihormonal Cancer Therapies Market Share by Region: 2023 VS 2030
Figure 16. Global Antihormonal Cancer Therapies Market Share by Players in 2023
Figure 17. Global Top Antihormonal Cancer Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihormonal Cancer Therapies as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Antihormonal Cancer Therapies Revenue in 2023
Figure 19. North America Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Antihormonal Cancer Therapies Market Share by Country (2019-2030)
Figure 21. United States Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Antihormonal Cancer Therapies Market Share by Country (2019-2030)
Figure 25. Germany Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Antihormonal Cancer Therapies Market Share by Region (2019-2030)
Figure 33. China Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Antihormonal Cancer Therapies Market Share by Country (2019-2030)
Figure 41. Mexico Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Antihormonal Cancer Therapies Market Share by Country (2019-2030)
Figure 45. Turkey Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Antihormonal Cancer Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Roche Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 48. Amgen Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 49. Samyang Biopharmaceuticals Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 50. Tolmar Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 51. Bluebird Bio Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 53. Exelixis Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 54. Guardant Health Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 55. Illumina Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 56. Novartis Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 57. Merck KGaA Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 58. AbbVie Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 59. Gilead Sciences Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 60. Johnson & Johnson Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 61. Pfizer Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 62. Takeda Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 63. Eli Lilly Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 64. AstraZeneca Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 65. Astellas Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 66. Merck & Co. Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 67. Sanofi Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 68. Bayer Revenue Growth Rate in Antihormonal Cancer Therapies Business (2019-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
